Karachi: GlaxoSmithKline Pakistan Limited has announced that its Board of Directors will convene a virtual meeting to discuss the company's annual accounts for the fiscal year ending December 31, 2024. The meeting is scheduled to take place on March 24, 2025, at 12 noon, originating from the company's head office located at 35-Dockyard Road, West Wharf, Karachi.

The company has instituted a closed period from March 17, 2025, to March 24, 2025, in accordance with the Corporate Governance Regulations and requirements of the Pakistan Stock Exchange (PSX). During this time, no director, CEO, or executive of GlaxoSmithKline Pakistan Limited is permitted to engage in any transactions involving the company's shares, either directly or indirectly.

This measure aligns with clause 5.6.4 of the PSX regulations, which mandates a closed period preceding board meetings where financial results are considered. Employees of GlaxoSmithKline Pakistan have been duly informed of this restriction to ensure compliance.

According to information available from the Pakistan Stock Exchange (PSX), stakeholders and TRE Certificate Holders have also been notified of the closed period and the forthcoming board meeting. The pharmaceutical company is categorized under the designated market category on the stock exchange, reflecting its status and regulatory obligations within the market.